Naoka Hironiwa
Research Subjects
Naoka Hironiwa has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Akihisa Sakamoto
Research Division, Chugai Pharmaceutical, Yokohama, Kanagawa, Japan
35 shared publications - Haruka Kuroi
Discovery Biologics Department, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan
35 shared publications - Hirofumi Mikami
Research Division, Chugai Pharmaceutical, Yokohama, Kanagawa, Japan
35 shared publications - Junko Shinozuka
Research Division, Chugai Pharmaceutical, Yokohama, Kanagawa, Japan
35 shared publications - Mika Kamata-Sakurai
Chugai Pharmaceutical Co Ltd, Yokohama, Kanagawa, Japan
35 shared publications - Takehisa Kitazawa
Chugai Pharmaceutical Co., Ltd. 2 Research Division Yokohama, Japan
35 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S6. Cross-reactivity of DLL3 trispecific.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S6. Cross-reactivity of DLL3 trispecific.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S2. Overview of the generation of the CD3/CD137 dual-specific Fab
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S2. Overview of the generation of the CD3/CD137 dual-specific Fab
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S7. DLL3 expression of SCLC xenograft models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S7. DLL3 expression of SCLC xenograft models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S4. DLL3 trispecific induces multiple cytokine production and DLL3- dependent cytotoxicity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S4. DLL3 trispecific induces multiple cytokine production and DLL3- dependent cytotoxicity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S8. DLL3 trispecific induced activation of tumor-infiltrating T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S8. DLL3 trispecific induced activation of tumor-infiltrating T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S5. DLL3 trispecific induces cytotoxicity against non-SCLC tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S5. DLL3 trispecific induces cytotoxicity against non-SCLC tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Pharmacokinetic parameters of DLL3 trispecific in cynomolgus monkeys
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Pharmacokinetic parameters of DLL3 trispecific in cynomolgus monkeys
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S9. The use of dexamethasone and tocilizumab does not limit the antitumor efficacy of DLL3 trispecific.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S9. The use of dexamethasone and tocilizumab does not limit the antitumor efficacy of DLL3 trispecific.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S1. The composition of the antibodies
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S1. The composition of the antibodies